The latest update is out from Biome Australia Ltd ( (AU:BIO) ).
Biome Australia Ltd has announced a new co-investment agreement with Australia’s Food and Beverage Accelerator (FaBA) to develop its Lactobacillius plantarum BMB18 probiotic strain. The partnership, supported by significant government funding, allows Biome to retain full ownership of any intellectual property developed and potentially reduce future R&D costs, bolstering its positioning in the microbiome health industry.
More about Biome Australia Ltd
Biome Australia Ltd is a microbiome health company engaged in the development of probiotic strains. The company focuses on creating innovative solutions in the health sector, particularly around the modulation of immune responses, inflammation reduction, and maintaining intestinal health.
YTD Price Performance: -2.54%
Average Trading Volume: 571,053
Technical Sentiment Consensus Rating: Sell
See more data about BIO stock on TipRanks’ Stock Analysis page.